Shu Jin

1. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
   2021/10/18 by Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim +15 · 1 citation
   Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Treatments and Mutations #Cancer Immunotherapy and Biomarkers #Melanoma and MAPK Pathways #Medicine #Cohort #Internal medicine #Oncology #Retrospective cohort study #Response Evaluation Criteria in Solid Tumors #Chemotherapy #Progressive disease
2. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
   2021/02/25 by Gregory J. Riely, Joel W. Neal, D. Ross Camidge +19 · 1 citation
   Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Treatments and Mutations #PI3K/AKT/mTOR signaling in cancer #Colorectal Cancer Treatments and Studies #Medicine #Rash #Nausea #Lung cancer #Adverse effect #Internal medicine #Vomiting #Diarrhea #Phases of clinical research #Oncology #Mucositis #Clinical trial #Epidermal growth factor receptor #Gastroenterology #Population #Toxicity #Cancer